IMR Press / FBE / Volume 8 / Issue 1 / DOI: 10.2741/E750

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

ALK inhibitors for clinical use in cancer therapy

Show Less
1 Department of Health Sciences, University of Milano-Bicocca, Milano, Italy
2 European Research Initiative on ALK-related malignancies (ERIA)

*Author to whom correspondence should be addressed.

Academic Editor: Roberto Chiarle

Front. Biosci. (Elite Ed) 2016, 8(1), 46–60; https://doi.org/10.2741/E750
Published: 1 January 2016
(This article belongs to the Special Issue ALK: 20 years of discoveries)
Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of tumors, both solid and hematological. Few years ago crizotinib, an inhibitor of the receptor tyrosine kinases c-Met and ALK, demonstrated its activity in ALK positive non-small-cell lung cancer and other tumors with excellent toxicity profile. Subsequently several ALK inhibitors have been developed, offering new personalized treatment options. This review addresses some clinical considerations on the use of ALK inhibitors in ALK positive tumors and on the development of resistance to them.

Keywords
ALK-rearranged tumors
Crizotinib
Crizotinib-resistance
Next-generation ALK inhibitors
Review
Share
Back to top